<DOC>
	<DOCNO>NCT00265473</DOCNO>
	<brief_summary>This clinical trial design extend observation make pilot clinical trial ( IND 8971 , Study # 1 ) safety efficacy immunotherapy anti-CD3 monoclonal antibody hOKT3γ1 ( Ala-Ala ) , ( currently call MGA031 ) combine sirolimus tacrolimus prevent rejection autoimmune destruction decease donor pancreatic islet transplant type 1 diabetic recipient .</brief_summary>
	<brief_title>MGA031 , Sirolimus Tacrolimus Islet Transplantation</brief_title>
	<detailed_description>Type 1 diabetes mellitus continue therapeutic challenge . Previous study show failure prevent hypoglycemia hyperglycemia result acute chronic complication , lead poor quality life , premature death , considerable health care cost 30 % 50 % diabetic patient . Therefore , establish safe effective way achieve maintain normoglycemia would substantial implication well-being individual diabetes . Intensive insulin therapy show reduce risk chronic complication patient achieve near-normalization glycemia . However , therapy labor-intensive , difficult implement many patient , limited accompany increased frequency severe hypoglycemia . Currently , way restore sustain normoglycemia without associate risk hypoglycemia replace patient 's islet Langerhans , either transplant vascularize pancreas , much less invasively , infuse isolated islet . Strategies selectively inactivate autoreactive T cell prevent allorejection transplant islet absence diabetogenic side effect need develop islet transplant survive autoimmune diabetic recipient . The current clinical study extend observation make first pilot clinical trial ( IND 8971 , Study # 1 ) provide preliminary information safety efficacy immunotherapy anti-CD3 monoclonal antibody hOKT3γ1 ( Ala-Ala ) , ( currently call MGA031 ) combine sirolimus tacrolimus prevent rejection autoimmune destruction decease donor pancreatic islet transplant type 1 diabetic recipient . In pilot study 4 6 single islet transplant recipient remain insulin independent normal HbA1c episodes hypoglycemia throughout 1 year post-transplant period . Three four participant maintain insulin independence &gt; 3.5 , &gt; 4.5 &gt; 5 year post islet transplant . These preliminary finding warrant extension study involve recipient comprehensive immunologic monitoring examine great detail impact MGA031 induction immunotherapy T cell response operative rejection autoimmune destruction transplant islet well formation regulatory T cell function protection transplant islet . A total 5 patient type 1 diabetes transplant protocol . Islet transplant recipient admit 5 day follow one year transplantation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Age 18 65 year age . 2 . Ability provide write informed consent . 3 . Mentally stable able comply procedure study . 4 . Clinical history compatible type 1 diabetes onset disease &lt; 40 year age insulindependence &gt; 5 year time enrollment . 5 . Absent stimulate Cpeptide ( &lt; 0.3ng/ml ) response mixed meal tolerance test . 6 . Involvement intensive diabetes management define self monitor glucose value less mean three time day average week administration three insulin injection day insulin pump therapy . Such management must direction endocrinologist , diabetologist , diabetes specialist least 3 clinical evaluation previous 12 month . 7 . At least one episode severe hypoglycemia past 3 year define event symptom compatible hypoglycemia subject require assistance another person associate either blood glucose level &lt; 50 mg/dl prompt recovery oral carbohydrate , intravenous glucose , glucagon administration ) . 8 . Reduced awareness hypoglycemia . 1 . Any previous transplant . 2 . BMI &gt; 27 kg/m2 patient weight ≤ 50kg . 3 . Insulin requirement &gt; 0.8 IU/kg/day 50 IU/day . 4 . HbA1c &gt; 10 % . 5 . Untreated proliferative diabetic retinopathy . 6 . Uncontrolled Hypertension . 7 . Estimated glomerular filtration rate &lt; 70 ml/min/1.73 m2 female &lt; 80 ml/min/1.73 m2 males 8 . Presence history macroalbuminuria ( &gt; 300mg/d ) . 9 . Presence history panelreactive antiHLA antibody &gt; 20 % flow cytometry . 10 . Females : Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study 3 month discontinuation . Males : intent procreate duration study within 3 month discontinuation unwillingness use effective measure contraception . 11 . Active infection . 12 . Negative screen EpsteinBarr Virus ( EBV ) . 13 . Invasive aspergillus infection within one year prior study entry . 14 . Any history malignancy except completely resect squamous basal cell carcinoma skin . 15 . Active alcohol , tobacco substance abuse . 16 . Baseline Hgb low limit normal local laboratory ; lymphopenia , neutropenia , thrombocytopenia . 17 . A history Factor V deficiency . 18 . Any coagulopathy medical condition require longterm anticoagulant therapy . 19 . Severe coexist cardiac disease . 20 . Persistent elevation liver function test . 21 . Symptomatic cholecystolithiasis . 22 . Acute chronic pancreatitis . 23 . Symptomatic peptic ulcer disease . 24 . Unremitting diarrhea , vomit gastrointestinal disorder potentially interfere absorption . 25 . Hyperlipidemia despite medical therapy ( fast LDL cholesterol &gt; 130 mg/dl , treat untreated ; and/or fast triglyceride &gt; 200 mg/dl ) . 26 . Chronic use systemic steroid . 27 . Use investigational agent within 4 week participation . 28 . Administration live attenuate vaccine ( ) within 2 month enrollment . 29 . Any medical condition , opinion investigator , interfere safe completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>